000448023 000__ 01543nam\a2200445Ia\4500
000448023 001__ 448023
000448023 003__ MiAaPQ
000448023 005__ 20211102003834.0
000448023 006__ m\\\\\o\\d\\\\\\\\
000448023 007__ cr\cn\nnnunnun
000448023 008__ 050202s2005\\\\ne\\\\\\o\\\\\001\0\eng\d
000448023 010__ $$z  2005040638
000448023 020__ $$z9780123693709
000448023 020__ $$z0123693705 (alk. paper)
000448023 035__ $$a(MiAaPQ)EBC294538
000448023 035__ $$a(Au-PeEL)EBL294538
000448023 035__ $$a(CaPaEBR)ebr10186063
000448023 035__ $$a(CaONFJC)MIL100533
000448023 035__ $$a(OCoLC)469589848
000448023 040__ $$aMiAaPQ$$cMiAaPQ$$dMiAaPQ
000448023 050_4 $$aHD9999.B442$$bB542 2005
000448023 08204 $$a174/.96606$$222
000448023 24500 $$aBioindustry ethics/$$cDavid L. Finegold ... [et al.].
000448023 260__ $$aAmsterdam ;$$aBoston :$$bElsevier Academic Press,$$cc2005.
000448023 300__ $$axi, 367 p.
000448023 336__ $$atext$$2rdacontent
000448023 337__ $$acomputer$$2rdamedia
000448023 338__ $$aonline resource$$2rdacarrier
000448023 500__ $$aIncludes index.
000448023 506__ $$aAccess limited to authorized users.
000448023 650_0 $$aBiotechnology industries$$xMoral and ethical aspects$$vCase studies.
000448023 650_0 $$aPharmaceutical industry$$xMoral and ethical aspects$$vCase studies.
000448023 650_0 $$aBusiness ethics$$xMoral and ethical aspects$$vCase studies.
000448023 655_0 $$aElectronic books
000448023 7001_ $$aFinegold, David.
000448023 852__ $$bebk
000448023 85640 $$3ProQuest Ebook Central Academic Complete $$uhttps://univsouthin.idm.oclc.org/login?url=https://ebookcentral.proquest.com/lib/usiricelib-ebooks/detail.action?docID=294538$$zOnline Access
000448023 909CO $$ooai:library.usi.edu:448023$$pGLOBAL_SET
000448023 980__ $$aBIB
000448023 980__ $$aEBOOK
000448023 982__ $$aEbook
000448023 983__ $$aOnline